OIPE JC184
AUG 0 2 2001
PATENT & TRADEMARK OFFICE

RECEIVED
AUG 07 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Yeh et al.	**GROUP:**	1615
SERIAL NO:	09/847,017	**EXAMINER:**	Unknown
FILED:	May 1, 2001		
FOR:	A PROCESS FOR THE PREPARATION OF DIRECT TABLETTING FORMULATIONS AND AIDS		

RECEIVED
AUG 06 2001
TC 1700

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In compliance with 37 C.F.R. §§1.56, 1.97, and 1.98, Applicant submits copies of the documents listed on the attached Form PTO-1449. Also enclosed is a statement as to the relevancy of the non-translated foreign patents.

The Commissioner is authorized to charge Deposit Order Account No. 19-0079 for any further fee that is required.

Respectfully submitted,

Arlene J. Powers
Registration No. 35,985
Samuels, Gauthier & Stevens, LLP
225 Franklin Street, Suite 3300
Boston, Massachusetts 02110
Telephone: (617) 426-9180
Extension 110

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United State Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Sarah Kennedy

7/31/01
Date

Comments on non-English-language references pursuant to Rule 98 for the Information Disclosure Statement of Patent Application Serial No. 09/847,017 (A Process for the Preparation of Direct Tabletting Formulations and Aids)

DE-C 3 506 276 disclosed a combination of α-lactose monohydrate and powdered cellulose for direct tabletting. Although this composition has a high binding capacity, it has no disintegration-promoting properties, especially when the compressive forces are relatively high.

DE-A 35 05 433 disclosed another combination of α-lactose monohydrate and polyvinyl pyrrolidone as binder, and crosslinked, insoluble polyvinyl pyrrolidone to promote disintegration. This direct tabletting aid has excellent flow properties and results, without further addition of a disintegrant, in rapidly disintegrating tablets. However, it is less suitable for high-dose active substances whose compressibility is poor, because its uptake capacity for active substances to form tablets with sufficient mechanical stability is limited.